Uncategorized

Lipid nanoparticle technology: poised to have a revolutionary impact

In a new review article published in Advanced Drug Delivery Reviews, NMIN researchers and colleagues discuss the use of state-of-the-art lipid nanoparticle (LNP) technology for therapeutic gene regulation in the liver. LNP technology enables the delivery of nucleic acids to treat liver diseases, addressing the root causes of these diseases… Read More »Lipid nanoparticle technology: poised to have a revolutionary impact

NMIN research leader discusses new diagnostic technology as key to “pandexit”

NMIN Research Leader Dr. Shana Kelley discusses how new rapid diagnostic technologies could transform the way the COVID-19 pandemic is managed, in a webinar recorded on July 7, 2020. https://youtu.be/Zj4-N_CyuRg In the video, Dr. Kelley discusses innovative technologies being developed by researchers in her multidisciplinary PRiME group, including NMIN researcher… Read More »NMIN research leader discusses new diagnostic technology as key to “pandexit”

Meet April O’Connell, NMIN’s new Manager, Research & Partnerships

As of July 13, 2020, NMIN has a new Manager of Research and Partnerships: April O’Connell, BA, CHRP, CHRL. April brings eight years’ experience managing a multimillion-dollar research portfolio for AllerGen NCE. April was nationally recognized in 2019 for excellence in research management by the Canadian Association of Research Administrators… Read More »Meet April O’Connell, NMIN’s new Manager, Research & Partnerships

NMIN researchers awarded CIHR funding for COVID-19 projects

Two NMIN researchers based at the University of British Columbia (UBC) have been awarded CIHR funding to support projects addressing COVID19-related health challenges. NMIN’s Scientific Director, Dr. Pieter Cullis, was awarded $237,445 in support of his effort to develop an antibody therapy for COVID-19. The project, seed-funded by NMIN, will… Read More »NMIN researchers awarded CIHR funding for COVID-19 projects

NMIN welcomes three new Board members

The NanoMedicines Innovation Network (NMIN) is pleased to welcome the following new members to its Board of Directors (L to R above): Vanessa Grant, Partner, Norton Rose Fulbright Canada LLP Inès Holzbaur, Co-Founder & Managing Partner, AmorChem David Martin, Managing Director & Head of Equity Research, Bloom Burton Securities “We… Read More »NMIN welcomes three new Board members

Soil stops bleeding: NMIN researcher

NMIN research co-leader Dr. Christan Kastrup and his research team find that soil silicates play a key role in blood clotting Research led by Dr. Christian Kastrup and published in Blood Advances has found that soil silicates in wounds help activate a blood known as protein coagulation Factor XII. This… Read More »Soil stops bleeding: NMIN researcher

The Ins & Outs of Gene Therapy Drug Development: an interview with NMIN’s Scientific Director

In an insightful 42-minute interview, NMIN’s Scientific Director Dr. Pieter Cullis, a pioneer in liposomal gene and drug delivery, discusses his scientific career with a focus on his contributions to the evolution of gene therapy. https://www.youtube.com/watch?v=ERU-3b6YtUkThe interview was conducted on behalf of the Gene Delivery and Gene Editing focus group… Read More »The Ins & Outs of Gene Therapy Drug Development: an interview with NMIN’s Scientific Director